United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC trimmed its position in United Therapeutics Co. (NASDAQ:UTHR) by 3.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,760,300 shares of the biotechnology company’s stock after selling 98,588 shares during the period. United Therapeutics accounts for approximately 13.8% of Avoro Capital Advisors LLC’s investment portfolio, making the stock its biggest holding. Avoro Capital Advisors LLC owned about 6.18% of United Therapeutics worth $973,944,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its position in United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 30 shares during the last quarter. Parallel Advisors LLC raised its holdings in United Therapeutics by 2.8% in the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 30 shares during the period. Anchor Investment Management LLC raised its stake in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after buying an additional 30 shares during the period. Great Lakes Advisors LLC grew its stake in United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after acquiring an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its holdings in United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after purchasing an additional 33 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $940,373.07. The trade was a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $10,437,712.18. The trade was a 23.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 91,500 shares of company stock valued at $30,971,540. Insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $284.73 on Monday. United Therapeutics Co. has a 12 month low of $233.28 and a 12 month high of $417.82. The company has a market capitalization of $12.79 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The firm’s fifty day moving average price is $316.61 and its 200 day moving average price is $348.62.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the company posted $4.36 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the subject of several recent research reports. UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.